🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Italy / NCT06965673
Recruiting Not applicable

Assessment of Eye Movements in Stroke Patients and Closed-loop Intervention

NCT06965673 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2023-04-01
Last updated
2025-05-11

Condition(s) studied

Stroke

Investigational drug(s) / intervention(s)

Visual exploration trainingStandard neuropsychological rehabilitation

Visual exploration training: Visual exploration of natural scenes guided by closed-loop auditory biofeedback through eye-tracking

Standard neuropsychological rehabilitation: Standard rehabilitation delivered at the IRCCS San Camillo hospital

Study summary

The current study evaluates first the assumption that eye-movements during free viewing behavior are potential biomarkers of visuospatial deficits in stroke population. Second, it assesses the feasibility of a novel visual exploration training to ameliorate visuospatial deficits, by exploiting an auditory biofeedback system coupled with online parsed fixations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Vigilant * First unifocal ischemic or hemorragic stroke * Presence of maximum two lacunae, clinically silent, smaller than 15 mm. in the structural MRI * Evident symptoms in the visual, attentive, memory, motor or language domain supported by the radiological exam Exclusion Criteria: * Previous stroke history, visible at the radiological exam * Multifocal deficit * Incapacity to remain vigilant during the required assessments * Claustrophobia and/or metallic objects which could prevent MRI acquisition * Presence of other neurological, psychiatric or medical conditions which may undermine interpretation of behavioral and neuroimaging results

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Azienda Ospedaliera di Padova Padova PD Recruiting
IRCCS San Camillo Venice-Lido VE Recruiting

More IRCCS San Camillo, Venezia, Italy trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06965673 on ClinicalTrials.gov ↗ ← All trials in Italy